Israel examining heart inflammation cases in people who received Pfizer COVID shot

Pfizer COVID

Israel examining heart inflammation cases in people who received Pfizer COVID shot

Pfizer (NYSE:PFE) UP 0.05% AT 38.66

Israel’s Health Ministry said on Sunday it is examining a small number of cases of heart inflammation in people who had received Pfizer (NYSE:PFE)’s COVID-19 vaccine, though it has not yet drawn any conclusions.

Pfizer said it has not observed a higher rate of the condition than would normally be expected in the general population.

Israel’s pandemic response coordinator, Nachman Ash, said that a preliminary study showed “tens of incidents” of myocarditis occurring among more than 5 million vaccinated people, primarily after the second dose.

Ash said it was unclear whether this was unusually high and whether it was connected to the vaccine.

Most of the cases were reported among people up to age 30.

On technical fronts Pfizer (NYSE:PFE) RSI stood at 38.66 and currently stock is trading Above 20 and 50 Days MA and Below 5 Days Moving Averages. So, SELL position can be taken with following target and stoploss.

TRADE SIGNAL -: Pfizer (NYSE:PFE) – SELL: 38.64, TARGET: 38.41 , STOP LOSS: 38.87

About Author

Related posts

Leave a Reply